CHFT recruit first national patients for FOXTROT2 study.
Calderdale and Huddersfield NHS Foundation Trust have recruited the nation’s first patients to the FOXTROT2 study.
After previously participating in the initial FOXTROT study, the site were eager to offer the second iteration to their patients.
FOXTROT2 is a phase III randomised trial that evaluates neoadjuvant chemotherapy in older and/or frail patients with locally advanced but operable colon cancer.
The site opened to recruitment for the trial on February 7th 2022 which made CHFT the first site nationally to open the study. The first patient was then consented on March 18th, and subsequently randomised on the 21st.
Dr Sam Turnbull, FOXTROT2 Principal Investigator said,
“The strengths of research and recruitment at CHFT are rooted in how we work as a team and the communication between the research team, clinicians and MDT. There is a demonstrable benefit to patients involved in research and patients treated in centres with a strong research focus. We were very keen to be involved with FOXTROT2 as we believe that involvement in clinic trials should be available to everyone and the advantage of this trial is that it focuses specifically on a previously underrepresented group”.
